BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol 2016; 22(12): 3418-3431 [PMID: 27022224 DOI: 10.3748/wjg.v22.i12.3418]
URL: https://www.wjgnet.com/1948-5182/full/v22/i12/3418.htm
Number Citing Articles
1
Dorota Zarębska-Michaluk, Robert Flisiak, Marta Flisiak-Jackiewicz. Management of hepatitis B and hepatitis C coinfection: an expert reviewExpert Review of Anti-infective Therapy 2020; 18(10): 1033 doi: 10.1080/14787210.2020.1776112
2
Michael P. Manns, Benjamin Maasoumy. Breakthroughs in hepatitis C research: from discovery to cureNature Reviews Gastroenterology & Hepatology 2022;  doi: 10.1038/s41575-022-00608-8
3
Xiaoqiong Duan, Xinzhong Liao, Shilin Li, Yujia Li, Min Xu, Yancui Wang, Haiyan Ye, Hang Zhao, Chunhui Yang, Xiang Zhu, Limin Chen. Transmembrane protein 2 inhibits Zika virus replication through activation of the Janus kinase/signal transducers and activators of transcription signaling pathwayFuture Virology 2019; 14(1): 9 doi: 10.2217/fvl-2018-0115
4
Dorota Zarębska-Michaluk, Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda, Małgorzata Pawłowska, Ewa Janczewska, Hanna Berak, Justyna Janocha-Litwin, Jakub Klapaczyński, Krzysztof Tomasiewicz, Anna Piekarska, Rafał Krygier, Jolanta Citko, Olga Tronina, Krystyna Dobrowolska, Robert Flisiak. Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV CoinfectionJournal of Clinical Medicine 2022; 11(2): 389 doi: 10.3390/jcm11020389
5
D T Abdurakhmanov, T P Rozina, E N Nikulkina, E Z Burnevich, E L Tanashuk, M V Severov, A L Filatova, S Yu Milovanova, V V Karpov, S V Moiseev. Antiviral therapy of chronic hepatitis C: 30 years success storyTerapevticheskii arkhiv 2019; 91(11): 110 doi: 10.26442/00403660.2019.11.000470
6
Na Yang, Chaomin Sun, Lixin Zhang, Jianguo Liu, Fuhang Song. Identification and Analysis of Novel Inhibitors against NS3 Helicase and NS5B RNA-Dependent RNA Polymerase from Hepatitis C Virus 1b (Con1)Frontiers in Microbiology 2017; 8 doi: 10.3389/fmicb.2017.02153
7
Iandra Holzmann, Cristiane V. Tovo, Roseline Minmé, Mônica P. Leal, Michele P. Kliemann, Camila Ubirajara, Amanda A. Aquino, Bruna Araujo, Paulo R.L. Almeida. Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in BrazilThe Brazilian Journal of Infectious Diseases 2018; 22(4): 317 doi: 10.1016/j.bjid.2018.06.004
8
Seyed Moayed Alavian, Mohammad Saeid Rezaee-Zavareh. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisHepatitis Monthly 2016; 16(9) doi: 10.5812/hepatmon.41077
9
K. Rajender Reddy, Stanislas Pol, Paul J. Thuluvath, Hiromitsu Kumada, Joji Toyota, Kazuaki Chayama, James Levin, Eric J. Lawitz, Adrian Gadano, Wayne Ghesquiere, Guido Gerken, Maurizia R. Brunetto, Cheng-Yuan Peng, Marcelo Silva, Simone I. Strasser, Jeong Heo, Fiona McPhee, Zhaohui Liu, Rong Yang, Misti Linaberry, Stephanie Noviello. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimensLiver International 2018; 38(5): 821 doi: 10.1111/liv.13596
10
Paweł Pabjan, Michał Brzdęk, Magdalena Chrapek, Kacper Dziedzic, Krystyna Dobrowolska, Katarzyna Paluch, Anna Garbat, Piotr Błoniarczyk, Katarzyna Reczko, Piotr Stępień, Dorota Zarębska-Michaluk. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?Viruses 2022; 14(1): 96 doi: 10.3390/v14010096
11
Xiaobo Zhu, Mingqi Wang, Mei Liu, Xinghao Yu, Peng Huang. Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infectionPersonalized Medicine 2019; 16(5): 421 doi: 10.2217/pme-2018-0121